Skip to content

Study · Animal study (in vivo) · rat · 1989

4 results

MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny.

Saleh MI, Kostrzewa RM

Peptides1 Jan 1989Cited by 11 (Europe PMC)

PMID2568624 (opens in a new tab)DOI10.1016/0196-9781(89)90072-7 (opens in a new tab)PepBankPUB-02568624
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, MIF‑1 alone had no effect on striatal spiroperidol binding.

    In plain wordsIn rats, MIF‑1 alone did not affect striatal spiroperidol binding.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeStriatal spiroperidol binding with MIF-1 alone
    Study

    ratn: not reported in source

    postnatal striatal dopamine receptor development
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 mg/kg/day · intraperitoneal · 32 days from birthAs given in this study (rat).

    Source sentences

    Summary
    While MIF-1 alone (1.0 mg/kg/day, IP, x32 days from birth) had no effect on [3H]spiroperidol binding,
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, MIF‑1 completely attenuated spiroperidol-induced impairment of striatal D2 receptor development.

    In plain wordsIn rats, MIF‑1 prevented impaired D2 receptor development compared with spiroperidol alone.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseD2 receptor ontogenic impairment
    Study

    ratn: not reported in source

    postnatal striatal dopamine receptor development
    Comparator
    spiroperidol alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 mg/kg/day · intraperitoneal · 32 days from birthAs given in this study (rat).

    Source sentences

    Summary
    While MIF-1 alone (1.0 mg/kg/day, IP, x32 days from birth) had no effect on [3H]spiroperidol binding, MIF-1 completely attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol treatment.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, striatal binding Bmax after spiroperidol plus MIF‑1 was at the saline control level at 5 weeks.

    In plain wordsIn rats, spiroperidol plus MIF‑1 produced a receptor binding capacity similar to saline controls.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeSpiroperidol binding Bmax at 5 weeks
    Study

    ratn: not reported in source

    postnatal striatal dopamine receptor development
    Comparator
    saline control
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 mg/kg/day · intraperitoneal · 32 days from birthAs given in this study (rat).

    Source sentences

    Summary
    At 5 weeks the Bmax for [3H]spiroperidol binding was at the saline control level in the group of rats cotreated with spiroperidol and MIF-1.
    1 context sentence
    Summary · context
    While MIF-1 alone (1.0 mg/kg/day, IP, x32 days from birth) had no effect on [3H]spiroperidol binding, MIF-1 completely attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol treatment.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, specific striatal binding after spiroperidol plus MIF‑1 remained at control levels at 8 weeks without additional treatment.

    In plain wordsIn rats, spiroperidol plus MIF‑1 produced receptor binding similar to controls after treatment stopped.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeSpecific spiroperidol binding at 8 weeks
    Study

    ratn: not reported in source

    postnatal striatal dopamine receptor development
    Comparator
    control
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 mg/kg/day · intraperitoneal · 32 days from birthAs given in this study (rat).

    Source sentences

    Summary
    At 8 weeks, with no additional treatments, the specific binding of [3H]spiroperidol to striatum was also at control levels in the group cotreated with spiroperidol and MIF-1.
    1 context sentence
    Summary · context
    While MIF-1 alone (1.0 mg/kg/day, IP, x32 days from birth) had no effect on [3H]spiroperidol binding, MIF-1 completely attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.